Nunes-Tamashiro José Carlos, Natour Jamil, Ramuth Fernando Maier, Toffolo Sandra Regina, Mendes Jamile Godoy, Rosenfeld André, Furtado Rita Nely Vilar
Academic of Rheumatology Division, 58804from Universidade Federal de São Paulo- Escola Paulista de Medicina (Unifesp - EPM), Sao Paulo, Brazil.
Professor of Rheumatology Division and Head of Ambulatory of Rheumatology Interventions, 28105from Universidade Federal de São Paul o- Escola Paulista de Medicina (Unifesp - EPM), Sao Paulo, Brazil.
Clin Rehabil. 2022 Jul;36(7):900-915. doi: 10.1177/02692155221090407. Epub 2022 Apr 4.
To compare the effectiveness of intra-articular injection (IAI) of Platelet-Rich Plasma (PRP) with Triamcinolone Hexacetonide (TH) and Saline Solution (SS), in patients with knee osteoarthritis (OA).
A randomized controlled trial, with blinded patients and assessor.
Outpatient rheumatology service.
Patients with knee osteoarthritis grades II and III.
Patients received IAI with PRP, 40 mg TH, or SS.
Patients were assessed at baseline and after 4, 8, 12 e 52 weeks with: visual analogue scale (VAS) for pain at rest and movement, WOMAC questionnaire, Timed to Up and Go test, 6-min walk test, percentage of improvement, goniometry, quality of life SF-36 questionnaire, Likert scale and Kelgreen & Lawrence (KL) radiographic scale (only at baseline and 52 weeks).
100 patients were studied, with a mean age of 67.13(6.56) years. The TH group was superior for: percentage of improvement (versus SS group from 4 to 52 weeks); WOMAC total and pain (versus PRP group at 4 weeks); and WOMAC stiffness (versus SS group at 12 weeks). The SS group was inferior for WOMAC function (from 8 to 52 weeks). The PRP group showed lowest radiographic progression [TH 17 (51.51%) to 24 (72.72%); SS 17 (51.51%) to 30 (90.90%); PRP 20 (58.82%) to 21 (61.76%)].
The Triamcinolone Hexacetonide group was superior for percentage of improvement and WOMAC, pain and stiffness. For the WOMAC function, the Platelet-Rich Plasma group and Triamcinolone Hexacetonide group were superior to the Saline group. The Platelet-Rich Plasma group showed the lowest radiographic progression at 52 weeks of follow-up.
比较富血小板血浆(PRP)关节腔内注射(IAI)与己曲安奈德(TH)及生理盐水(SS)对膝骨关节炎(OA)患者的疗效。
一项随机对照试验,患者和评估者均为盲法。
门诊风湿病科。
膝关节骨关节炎II级和III级患者。
患者接受PRP、40mg TH或SS的关节腔内注射。
在基线时以及4、8、12和52周后对患者进行评估,评估指标包括:静息和活动时疼痛的视觉模拟量表(VAS)、WOMAC问卷、从坐到站测试、6分钟步行测试、改善百分比、测角法、生活质量SF - 36问卷、李克特量表以及凯尔格林和劳伦斯(KL)影像学量表(仅在基线和52周时)。
共研究了100例患者,平均年龄为67.13(6.56)岁。TH组在以下方面表现更优:改善百分比(与SS组相比,4至52周);WOMAC总分及疼痛(与PRP组相比,4周时);以及WOMAC僵硬(与SS组相比,12周时)。SS组在WOMAC功能方面较差(8至52周)。PRP组影像学进展最低[TH组从17例(51.51%)进展至24例(72.72%);SS组从17例(51.51%)进展至30例(90.90%);PRP组从20例(58.82%)进展至21例(61.76%)]。
己曲安奈德组在改善百分比以及WOMAC、疼痛和僵硬方面表现更优。对于WOMAC功能,富血小板血浆组和己曲安奈德组优于生理盐水组。富血小板血浆组在随访52周时影像学进展最低。